Acasti Pharma Stock EBITDA
ACST Stock | USD 3.40 0.01 0.29% |
Acasti Pharma fundamentals help investors to digest information that contributes to Acasti Pharma's financial success or failures. It also enables traders to predict the movement of Acasti Stock. The fundamental analysis module provides a way to measure Acasti Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acasti Pharma stock.
EBITDA is likely to gain to about 15 M in 2024. Acasti | EBITDA |
Acasti EBITDA Analysis
Acasti Pharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
More About EBITDA | All Equity Analysis
Acasti Pharma Ebitda |
|
EBITDA | = | Revenue | - | Basic Expenses |
Current Acasti Pharma EBITDA | 15.85 M |
Most of Acasti Pharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acasti Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Acasti EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Acasti Pharma is extremely important. It helps to project a fair market value of Acasti Stock properly, considering its historical fundamentals such as EBITDA. Since Acasti Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acasti Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acasti Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition |
Acasti Ebitda
Ebitda |
|
According to the company disclosure, Acasti Pharma reported earnings before interest,tax, depreciation and amortization of 15.85 M. This is 98.19% lower than that of the Pharmaceuticals sector and 84.18% lower than that of the Health Care industry. The ebitda for all United States stocks is 99.59% higher than that of the company.
Acasti EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acasti Pharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acasti Pharma could also be used in its relative valuation, which is a method of valuing Acasti Pharma by comparing valuation metrics of similar companies.Acasti Pharma is currently under evaluation in ebitda category among related companies.
Acasti Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Acasti Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acasti Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acasti Pharma's value.Shares | Bank Of America Corp | 2023-12-31 | 494.7 K | Two Sigma Securities, Llc | 2023-09-30 | 0.0 | Adar1 Capital Management Llc | 2023-12-31 | 34.5 K | Royal Bank Of Canada | 2023-12-31 | 31.6 K | Ubs Group Ag | 2023-12-31 | 5.6 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.9 K | Advisory Services Network, Llc | 2023-12-31 | 41.0 | Ica Group Wealth Management, Llc | 2023-12-31 | 9.0 | Nbc Securities Inc | 2023-09-30 | 2.0 | Td Waterhouse Canada Inc | 2023-12-31 | 0.0 | Jpmorgan Chase & Co | 2023-12-31 | 0.0 |
Acasti Fundamentals
Return On Equity | -0.48 | ||||
Return On Asset | -0.0792 | ||||
Current Valuation | 6.87 M | ||||
Shares Outstanding | 9.4 M | ||||
Shares Owned By Insiders | 16.02 % | ||||
Shares Owned By Institutions | 6.00 % | ||||
Number Of Shares Shorted | 6.59 K | ||||
Price To Earning | 15.34 X | ||||
Price To Book | 0.49 X | ||||
Price To Sales | 208.39 X | ||||
Gross Profit | 120 K | ||||
EBITDA | 15.85 M | ||||
Net Income | (42.43 M) | ||||
Cash And Equivalents | 38.39 M | ||||
Cash Per Share | 0.86 X | ||||
Total Debt | 485 K | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 11.13 X | ||||
Book Value Per Share | 6.88 X | ||||
Cash Flow From Operations | (15.91 M) | ||||
Short Ratio | 0.84 X | ||||
Earnings Per Share | (5.68) X | ||||
Target Price | 5.95 | ||||
Beta | 1.49 | ||||
Market Capitalization | 31.96 M | ||||
Total Asset | 79.12 M | ||||
Retained Earnings | (198.27 M) | ||||
Working Capital | 25.88 M | ||||
Current Asset | 11.33 M | ||||
Current Liabilities | 1.14 M | ||||
Z Score | 37.08 | ||||
Net Asset | 79.12 M |
About Acasti Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acasti Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acasti Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acasti Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
EBITDA | 14.3 M | 15 M |
Pair Trading with Acasti Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acasti Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acasti Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Acasti Stock
0.71 | MDGL | Madrigal Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
0.86 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Acasti Stock
0.73 | KA | Kineta Inc Report 29th of March 2024 | PairCorr |
0.57 | MBIO | Mustang Bio Report 3rd of April 2024 | PairCorr |
0.57 | MEIP | MEI Pharma Financial Report 9th of May 2024 | PairCorr |
0.57 | VBIV | VBI Vaccines Financial Report 20th of May 2024 | PairCorr |
0.57 | DBVT | DBV Technologies Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Acasti Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acasti Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acasti Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acasti Pharma to buy it.
The correlation of Acasti Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acasti Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acasti Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acasti Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Acasti Pharma Piotroski F Score and Acasti Pharma Altman Z Score analysis. For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Acasti Stock analysis
When running Acasti Pharma's price analysis, check to measure Acasti Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acasti Pharma is operating at the current time. Most of Acasti Pharma's value examination focuses on studying past and present price action to predict the probability of Acasti Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acasti Pharma's price. Additionally, you may evaluate how the addition of Acasti Pharma to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Acasti Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acasti Pharma. If investors know Acasti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acasti Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.68) | Revenue Per Share 0.005 | Return On Assets (0.08) | Return On Equity (0.48) |
The market value of Acasti Pharma is measured differently than its book value, which is the value of Acasti that is recorded on the company's balance sheet. Investors also form their own opinion of Acasti Pharma's value that differs from its market value or its book value, called intrinsic value, which is Acasti Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acasti Pharma's market value can be influenced by many factors that don't directly affect Acasti Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acasti Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Acasti Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acasti Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.